Clarivate PLC (NYSE:CLVT) Receives $3.22 Consensus Target Price from Analysts

Clarivate PLC (NYSE:CLVT) has been given a consensus recommendation of “Reduce” by the eight ratings firms that are currently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation and five have assigned a hold recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $3.2167.

Several brokerages have issued reports on CLVT. Royal Bank Of Canada dropped their price objective on Clarivate from $5.00 to $3.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Clarivate in a research note on Friday, March 27th. Citigroup reduced their price objective on Clarivate from $4.25 to $2.80 and set a “neutral” rating for the company in a research note on Wednesday, March 4th. Barclays reduced their price objective on Clarivate from $4.00 to $2.40 and set an “underweight” rating for the company in a research note on Wednesday, February 25th. Finally, Wall Street Zen raised Clarivate from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd.

Clarivate Stock Performance

Shares of CLVT stock opened at $2.46 on Friday. The stock’s 50-day moving average is $2.53 and its two-hundred day moving average is $2.85. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -11.69 and a beta of 1.41. Clarivate has a 1 year low of $1.66 and a 1 year high of $4.77. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.84 and a current ratio of 0.84.

Clarivate (NYSE:CLVT) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.04. The company had revenue of $585.50 million for the quarter, compared to analyst estimates of $569.50 million. Clarivate had a positive return on equity of 8.82% and a negative net margin of 5.61%.The business’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.14 earnings per share. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. Analysts predict that Clarivate will post 0.65 earnings per share for the current year.

Institutional Trading of Clarivate

Several institutional investors and hedge funds have recently added to or reduced their stakes in CLVT. Atairos Partners GP Inc. raised its stake in Clarivate by 195.3% during the 4th quarter. Atairos Partners GP Inc. now owns 10,232,667 shares of the company’s stock valued at $34,177,000 after acquiring an additional 6,767,667 shares during the last quarter. First Trust Advisors LP purchased a new stake in Clarivate during the 4th quarter valued at approximately $16,721,000. Balyasny Asset Management L.P. raised its stake in Clarivate by 827.6% during the 3rd quarter. Balyasny Asset Management L.P. now owns 4,882,593 shares of the company’s stock valued at $18,700,000 after acquiring an additional 4,356,232 shares during the last quarter. Bank of America Corp DE raised its stake in Clarivate by 506.9% during the 2nd quarter. Bank of America Corp DE now owns 2,870,668 shares of the company’s stock valued at $12,344,000 after acquiring an additional 2,397,670 shares during the last quarter. Finally, Man Group plc raised its stake in Clarivate by 228.1% during the 2nd quarter. Man Group plc now owns 3,091,139 shares of the company’s stock valued at $13,292,000 after acquiring an additional 2,148,943 shares during the last quarter. 85.72% of the stock is owned by hedge funds and other institutional investors.

Clarivate Company Profile

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.